



Hep C U Later – Hepatitis C Patient Identification Collaboration Joint Working Outcome Summary

Hep C U Later is commissioned by the NHS England Hepatitis C Elimination Programme and is an output of an NHS Addictions Provider Alliance (NHS APA initiative) and Gilead Sciences Joint Working Initiative.

Parties to the Joint Working:

1. The Midlands Partnership NHS Foundation Trust (MPFT) of Trust Headquarters, St Georges Hospital, Corporation Street, Stafford ST16 3SR
2. Gilead Sciences Ltd, a company registered in England (registration number: 02543818), having a principal place of business at 280 High Holborn, London WC1V 7EE

Start Date: July 2019
Project Extended: March 2022
Project Extended: September 2024

This report summarises outcomes from March 2022 to March 2026.

**For further details of outcomes to March 2022 please see NHS Addictions
Provider Alliance (Formally the NHS Substance Misuse Alliance) – Hepatitis C
Patient Identification - UKI-UNB-2825**

Introduction

The Hep C U Later Drug and Alcohol Focussed Programme:

Hep C U Later, is commissioned by the NHS England Hepatitis C Elimination Team

The NHS Addiction Providers Alliance (NHSAPA) is an alliance of NHS Trusts, providing community drug and alcohol treatment services across England, and is currently chaired by Inclusion (part of the Midlands Partnership NHS Foundation Trust).

This reach currently extends to over 49,000 people who use community drug and alcohol treatment services, across 19 NHS Trusts, 35 community drug service contracts, aligning with 15 of the 23 Operational Delivery Networks (ODNs). The NHS APA members provide community drug and alcohol services to approximately 35% of people engaged with community drug and alcohol services in the English treatment system. The system-wide partnership ensures providers collaborate closely, share learning and co-produce solutions to ultimately drive forward quality care. Hep C U Later is an initiative of the NHS APA.

The aims of the Hep C U Later Drug and Alcohol Focused NHS APA Programme are:

1. Reaching hepatitis C micro-elimination across all NHS APA member services
2. Improving the ability of the NHS APA services to sustain micro-elimination
3. Improving harm reduction in drug and alcohol services and widening opportunities to improve testing, treatment and awareness (outside of drug treatment services).

Hep C U Later – Hepatitis C Patient Identification Collaboration

Hep C U Later have been a key enabler in developing HCV micro-elimination, in partnership with Gilead Sciences, across NHS APA member services since 2020, feeding into the positive patient outcomes seen across the wider NHS England (NHSE) national elimination programme.

The aims and objectives of the Joint Working Project are:

- To bring benefits to patients and improve patient outcomes through high quality treatment and management with the stated aim of micro-eliminating hepatitis C in all drug and alcohol services across NHS Trusts which are part of the NHS Additions Provider Alliance (NHS APA) and to expand benefits across the wider UK region, sharing considerable expertise that has been built by Hep C U Later and Gilead Sciences.

Outcomes Summary:

**Other impact reports are available – for further details please see
HepCULater Impact Report – UK-UNB-3988 / May 2023 and HepCULater
Impact Report – UK-UNB-5977 / August 2024**

Work with community drug and alcohol treatment services has now helped 30 NHS community drug and alcohol treatment services reach hepatitis C micro-elimination, with many sustaining it, and many of these have now sustained this for over two years.

Testing across NHS APA sites has previously increased year-on-year, and recently stabilised as expected, supported by dashboards, analytics, and use of the NHSE Elimination Programme Funded Cepheid GeneXpert machines. The cartridge re-distribution pilot alone has saved the system thousands of pounds.

Work towards supporting services to sustain hepatitis C micro-elimination as an ongoing legacy is in full swing, with the release of the sustainability toolkit and the launch of the portable data dashboard – enabling services to manage their own data as part of business-as-usual processes.

Our Impact at a Glance

45,139 hepatitis C tests across the NHS APA since 2020	30 NHS APA services reached hepatitis C micro-elimination	Thousands of people across the NHS APA have been treated for hepatitis C since the start of the Hep C U Later programme
---	--	--


Testing:

It is important to note that overall testing numbers are much greater than shown owing to the number of services who have transferred to non-NHS APA providers in the last year due to the inability to access parts of the data. This data is taken from only current NHS APA member services and does not take into account any tests taken from NHS APA members who are no longer part of the programme.

Over 12,344 hepatitis C tests have been completed in the last year

A total of 45,139 hepatitis C tests have been taken over the course of the Hep C U Later project between March 2020 and March 2026.

Hepatitis C testing numbers per quarter (March 2020 to March 2026):



Treatment:

Across the NHS APA a steady number of people continue to receive hepatitis C treatment. Although 453 people have had their status changed to 'cleared by treatment' this number is higher due to not taking into account the number of people currently on treatment or awaiting an SVR and does not take into account the data of services which have transferred out of the NHS APA. The current total number of people who have had their status changed to cleared by treatment (with the aforementioned caveats) is 2,777.

The number of people receiving hepatitis C treatment continues to increase, whilst the number of people with an active hepatitis C infection declines.

Over the last year **453 people had their status changed to 'cleared by treatment'** across the NHS APA.

Portable Dashboard:

Over the past year the Hep C U Later Team have been developing the 'portable dashboard'. The intention for the portable dashboard is to give NHS community drug and alcohol treatment services the ability to run the dashboards themselves and is part of the legacy of supporting services to sustain hepatitis C micro-elimination.

Progress to hepatitis C micro-elimination:


As of the end of March 2026 the NHS APA has reached hepatitis C micro-elimination in 30 of its NHS community drug and alcohol treatment services

Many NHS APA services have also re-declared hepatitis C micro-elimination at 6, 12,18 and 24 months of maintaining it

NHS APA Member NHS Trust Services Who Have Reached Hepatitis C Micro-Elimination	
1. Inclusion Thurrock - 2/6/22	16. Inclusion IOW - 26/10/23
2. Notts Clean Slate - 28/4/23	17. Inclusion Basingstoke - 26/10/23
3. CNWL Hounslow - 28/4/23	18. Inclusion Winchester - 26/10/23
4. Inclusion Fareham - 5/5/23	19. AWP BaNES – 21/2/24
5. Inclusion Gosport - 5/5/23	20. Pennine Care Stockport - 22/2/24
6. Mersey Care Brook Place - 13/6/23	21. Achieve Bury (GMMH) – 12/7/24
7. Inclusion Telford - 29/6/23	22. Notts Shared Care – 30/7/24
8. Inclusion Eastleigh - 2/8/23	23. Richmond (SLaM) – 4/10/24
9. Inclusion Bucks - 21/8/23	24. Milton Keynes (CNWL) – 7/10/24
10. Inclusion Aldershot - 4/9/23	25. Bristol ROADS (AWP) – 15/10/24
11. CNWL Hillingdon - 11/9/23	26. Trafford (GMMH) – 19/2/25
12. Inclusion Andover - 20/9/23	27. Nottingham Recovery Network – 1/5/25
13. Inclusion Havant - 20/9/23	28. Recovery Near You Wolverhampton (BSMHT) – 11/11/25
14. Inclusion New Forest - 20/9/23	29. East Riding, Goole (Humber) – 13/1/26
15. BSMHFT SIAS Solihull - 27/9/23	30. Salford (GMMH) – 30/1/26

The NHS APA has continued to work towards micro-elimination and is increasingly getting closer to meeting these measurements in all its services.

Trajectory of each micro-elimination criteria for the whole of the NHS APA over the period of the project:



NHS APA Service Activity

Midlands and North

The following is a breakdown of the progress over the last year.

Greater Manchester Mental Health NHS Foundation Trust – Achieve Services: Bolton, Bury, Salford & Trafford (GMMH):

- GMMH held testing events for World Hepatitis Day.
- GMMH were the first NHS Trust to take part in the NHS Addictions Provider Alliance Needle and Syringe Provision Quality Review, a review of all harm reduction services across the NHS community drug and alcohol treatment services.

- GMMH have remained committed to improving harm reduction across their services and within the community. Hep C U Later recently wrote a case study on the posters they have developed to reduce the risk of harm and BBV transmission from snorting cocaine in the night-time economy.

The Salford service achieved hepatitis C micro-elimination in January 2026!

The Bury service achieved hepatitis C micro-elimination in July 2025!

The Trafford service achieved hepatitis C micro-elimination in February 2026!

GMMH have micro-eliminated in three of their services – Bury, Salford and Trafford!

Pennine Care NHS Foundation Trust - Stockport:

- Pennine continue to maintain hepatitis C micro-elimination.
- Laura has delivered hepatitis C and micro-elimination criteria refresher training to staff at the service.

Pennine Care declared micro-elimination in January 2024 and continue to re-declare micro-elimination!

Nottinghamshire Healthcare NHS Foundation Trust - Nottingham Health Shop – Nottingham Recovery Network, Clean Slate & Shared Care:

- The Nottinghamshire services continue to sustain hepatitis C micro-elimination in their services and deliver dynamic approaches to testing, treatment, and harm reduction.
- The Health Shop took part in the NHS Addictions Provider Alliance Needle and Syringe Provision Quality Review, a review of all harm reduction services across the NHS community drug and alcohol treatment services.

Nottingham have declared micro-elimination in all three of their services – Shared Care, Clean Slate and the Nottingham Recovery Network! They continue to re-declare micro-elimination.

They were the first full service to declare micro-elimination across all of their services in the ODN.

Birmingham & Solihull Mental Health NHS Foundation Trust – Wolverhampton (RNY) & Solihull (SIAS):

Solihull –

- The service are aiming to confirm they have re-declared micro-elimination for two years.
- The service is committed to testing and finding people that may have hepatitis C as part of their continued commitment towards micro-elimination.

SIAS achieved micro-elimination in September 2023 and continue to re-declare!

Wolverhampton –

- The Hep C U Later team has supported the team with educational sessions.
- The service continues to maintain hepatitis C micro-elimination.

Wolverhampton achieved micro-elimination in November 2025!

East Riding, Humber Teaching NHS Foundation Trust:

- The Hep C U Later team led a BBV minimum standards meeting across the East Riding Partnership services.
- The Goole service achieved hepatitis C micro-elimination and the remaining services are on track to achieve this milestone.

The Goole service achieved micro-elimination in January 2026!

Inclusion - Staffordshire and Telford (part of Midlands Partnership University NHS Foundation Trust, MPFT):

Staffordshire –

- The Hep C U Later team have undertaken extensive data analysis improvement work across the 6 Staffordshire services. The team has met with keyworkers across the services to individually review caseloads, actions needed to reach micro-elimination, re-iterate processes around risk reviews, and ensured that staff know exactly how to record data correctly.
- The Hep C U Later team have also supported with education sessions, testing events, and placed a Cepheid GeneXpert machine at the service.
- A significant operational management plan has been put in place to ensure that the whole system is working toward not only micro-elimination, but also improving access to testing and treatment in the community.
- Staffordshire have started utilising Hepatitis C Trust Peers to distribute needle and syringe provision in the community using stock from the community drug and alcohol treatment service.

Telford –

- Telford held a testing event in their service for World Hepatitis Day.
- Telford took part in the NHS Addictions Provider Alliance Needle and Syringe Provision Quality Review, a review of all harm reduction services across the NHS community drug and alcohol treatment services.
- The Telford service continue to be committed to maintaining hepatitis C micro-elimination.

The Telford service achieved hepatitis C micro-elimination in June 2023 and have re-declared for 2 years!

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust (CNTW)

- The Hep C U Later team presented at the ODN meeting in July 2025.
- The Hep C U Later and Gilead Sciences team held a face-to-face BBV minimum standards workshop across CNTW services. With presentations from North East and North Cumbria ODN, UKHSA and The Hepatitis C Trust.
- The Hep C U Later team works closely with The Hepatitis C Trust peers across the region, supporting the recruitment and induction of a dedicated peer for Northumberland and North Tyneside.
- The Hep C U Later team continues to support the development of the Harm Reduction North-East Forum which is led by The Hepatitis C Trust. They are now part of the Steering Committee for the North East and North Cumbria Harm Reduction Forum along with representatives from OHID, The Hepatitis C Trust, Hepatology, Newcastle Council and Change Grow Live. There have been 3 very successful forums with around 65-100 people attending online each time. There are now 200 members of the forum.
- Significant data work has taken place across the CNTW patch, this includes cross referencing treatment information from HepCare with the service quarterly.
- Six-weekly senior leadership multi-disciplinary team meetings have been taking place.
- Continued support of the Clinical Van business case and planning with the ODN and key stakeholders. This included sharing Standard Operating Procedures and supporting the implementation of the Cepheid GeneXpert machine. The van arrived in January 2026.
- Delivered 'The Role of Harm Reduction in Reviewing the Risk of Blood Borne Virus Transmission' forums to the whole system in conjunction with another NHS APA member service (Portsmouth).

Newcastle –

- Continue to offer treatment on site and have treated over 45 people this year.
- Deep data work completed, particularly for criteria 4 of the hepatitis C micro-elimination criteria.
- Implemented new processes.
- Close to reaching micro-elimination.

North Tyneside –

- Hep C U Later met with senior management in June 2025 to discuss the new service model and establish roles and responsibilities for BBVs.
- Hep C U Later met with Waythrough staff and conducted deep data work.
- Carried out Hep C U Later 'magic data' training with the data team.
- The Hep C U Later team delivered training to the staff in June 2025.

Northumberland –

- The Hep C U Later team met with the Public Health Commissioner in Northumberland to discuss needle syringe provision
- The Hep C U Later team met with the new treatment nurse for Northumberland and completed deep data work which resulted in them meeting criteria 4 of the micro-elimination criteria for the first time.

South and London

The following is a breakdown of the progress over the last year:

Inclusion (Part of Midlands Partnership University NHS Foundation Trust, MPFT) – Hampshire, Isle of Wight (IOW), Wessex ODN Clinical Van, Buckinghamshire, Portsmouth:

Inclusion achieved hepatitis C micro-elimination in all of their services at the time in November 2023! Since then, all services have continued to re-declare!

Buckinghamshire –

- Delivered micro-elimination update training with the ODN.
- Working closely with the ODN Clinical Van.
- Redeclared micro-elimination after sustaining it for 2 years
- Met with ODN to discuss Primary Care work.
- Met with Thames Valley Secure Data environment.

The Buckinghamshire service achieved hepatitis C micro-elimination in August 2023 and have now sustained it for 2 years!

Portsmouth -

- Inclusion (MPFT) are subcontractors to the Society of St James (SSJ) in Portsmouth. Hep C U Later have been working with them on their commissioned BBV offer and ways to enhance it.
- Hep C U Later introduced a monthly stakeholder meeting with Local Authority Commissioners, The Hepatitis C Trust, the Wessex Clinical Van and Hepatology.
- Hep C U Later ran a training session with UKHSA for the Portsmouth SSJ Community Team, giving an overview of the history and importance of the UKHSA Unlinked Anonymous Survey of People Who Inject Drugs, and delivering a practical session on how to fill the survey and complete the dry blood spot test. Following this around 40 people were tested, and 17 samples were also sent to UKHSA for the 2026 Unlinked Anonymous Survey of People Who Inject Drugs.
- A significant drive in testing has resulted in Portsmouth being very close to reaching hepatitis C micro-elimination.
- High intensity test and treat weeks undertaken every quarter.

- The service and key stakeholders have been Identifying people who are on the UKHSA Return to Care database and engaging them.
- Pathway development work has taken place with HMP Winchester and HMP Bronzefield.
- A Cepheid GeneXpert machine remains on site, and regular training/confidence building sessions have been provided.
- Dedicated support for women with testing and awareness sessions at Project W.
- INHSU poster presented “One Source of The Truth.”

Hampshire –

The following Inclusion Hampshire services achieved hepatitis C micro-elimination:

- Andover – September 2023
- Aldershot – September 2023
- Basingstoke – October 2023
- Fareham – May 2023
- Gosport – May 2023
- Havant – September 2023
- Winchester – October 2023
- New Forest – September 2023
- Eastleigh – August 2023

All of the Inclusion Hampshire services have re-declared hepatitis C micro-elimination after sustaining it for two years!

- Hep C U Later have been working very closely with the Hep C Hants P2P team.
- The services have been identifying people who are on the UKHSA Return to Care database and engaging them in testing and treatment.
- A FibroScan pilot is being supported by the Hep C U Later team
- An initial meeting has been held to explore how a more formal liver health pathway might support individuals who are going to rehab across the Hampshire area. This pilot will involve working across multiple partners.
- All Inclusion Recovery Hampshire services, including the harm reduction van took part in the NHS Addictions Provider Alliance Needle and Syringe Provision Quality Review, a review of all harm reduction services across the NHS APA member community drug and alcohol treatment services.
- An INHSU abstract was submitted and accepted in partnership with Sheffield Pathology Laboratory on the hepatitis B anomalies in July 2024.

Isle of Wight (IOW) –

- New community pathways developed.
- Regular visits and meetings held.
- Work has taken place on contact tracing for new infections and for people who have been reinfected with the virus.
- The service has been identifying people who are on the UKHSA Return to Care database and engaging them.

- The Hep C U Later Team has been working with the service to explore developing the FibroScan and liver health monitoring offer. Work is underway to explore whether a further offer can be given to those at risk of liver disease through alcohol dependence and high alcohol consumption. This offer will include enhanced health and psychosocial work in the IOW.

The Isle of Wight service achieved hepatitis C micro-elimination in October 2023 and have sustained this for 2 years!

Wessex Clinical Van -

The Wessex clinical van is a Wessex ODN initiative which supports outreach hepatitis C testing and treatment across the region. The staff team operating the van are managed by Inclusion with operational oversight from Hep C U Later, therefore, it has been included in this report.

- Hep C U Later continued to provide strategic and operational support to the Wessex clinical van.
- Ran new GP projects in Portsmouth and Southampton to find people coded as 'hep C +' - to date over 75 people have been started on treatment – some of whom would not have been found otherwise. The local GP Hepatitis C Champion has developed a programme for the GP Trainees in the area which has been very successful.
- Hep C U Later has also been working on making regular reports much more automated, so that the data analyst from the Wessex Clinical Van team can produce the van team reports.
- The Wessex Clinical Van team provided an awareness and education session at the Southampton Civic Centre for World Health Day in April 2025.
- The Wessex Clinical Van released their 24/25 impact report in January 2025.

The Wessex Clinical Van won the UKPHR award for Collaborative Working!

Central & North West London NHS Foundation Trust – Hounslow, Ealing, Hillingdon, Brent, Milton Keynes (CNWL):

**Hounslow achieved hepatitis C micro-elimination in April 2023 and have re-declared micro-elimination for 2 years! They are about to complete their 3 year declaration
Hillingdon achieved micro-elimination in September 2023 and have maintained this for 2 years!**

Milton Keynes achieved hepatitis C micro-elimination in October 2024 and have re-declared for a year!

The CNWL services in their entirety have micro-eliminated hepatitis C!

- Hep C U Later coordinate the dashboards for Hillingdon, Hounslow and Milton Keynes and have supported Via with Brent and CGL with Ealing.
- Supported Ealing to declare hepatitis C micro-elimination.

- Louise attended Senior Management Meetings to update and agree strategies.
- 'Cost of Elimination Model' developed by Gilead using Hounslow to do the modelling.

Hounslow –

- Maintained micro-elimination for 2 years.
- Poster presented at INHSU on the 'Cost of Elimination Model'.
- Regular meetings with Data Lead and service.
- Bespoke training sessions were delivered.
- Hep C U Later linked the Find and Treat Team in with service.
- Quarterly Hounslow & Hillingdon Individualised Care Plans multi stakeholder meetings with ODN for the people with complex needs.

Hillingdon -

- Redeclared hepatitis C micro-elimination for 2 years and processes were put in place to sustain this.
- Regular stakeholder meetings held.

Milton Keynes -

- Project board continues to be held.
- New roles and responsibilities developed due to a new contract at Milton Keynes.
- System development put in place to re-declare hepatitis C micro-elimination.
- Utilisation of the ODN Clinical Van.
- Milton Keynes used the Cepheid GeneXpert machine.
- The service is working closely with the ODN.

South London & Maudsley NHS Foundation Trust - Richmond, Wandsworth, Lambeth, Bexley (SLaM):

Richmond micro-eliminated hepatitis C in October 2024!

- Hep C U Later has worked with the SLaM senior management to improve outcomes across all of the SLaM services, having presented on progress to micro-elimination at their senior management team meeting in January 2026.

Richmond and Wandsworth -

- The service and Hep C U Later are working with ODN and service to increase activity.
- Historic testing has been updated.
- Hep C U Later have delivered training to the teams.
- Supported the induction of the new nurse lead.
- Hep C U Later have been supporting the development of new testing contract.
- Deep data work and test updating has taken place.
- Monthly review meetings held with the ODN.

Bexley -

- Presented at the Bexley Combatting Drugs Partnership meeting.

- Meetings held with Public Health and the GP Champion.
- Supported Primary Care work in the area.
- Very close to reaching hepatitis C micro-elimination.
- Regular meetings held with the ODN.

Lambeth –

- Regular work on data anomalies carried out.
- Regular meetings held with the ODN.
- Deep data work carried out to review people who have a positive antibody status.
- Plans to complete a large data cleanse, then a High Intensity Test and Treat event.

Avon & Wiltshire Mental Health Partnership NHS Trust – BaNES (Bath), Bristol Roads and Dorset (AWP):

- Hep C U Later presented the Hep C U Later journey of Bristol and Bath at the ODN meeting.
- Hep C U Later handed over Bath and Bristol to Turning Point and had several meetings to ensure continuity of care for people and data integrity. Funding was also secured for a Hepatitis C Assertive Engagement Worker based at BDP.
- Hep C U Later continues to work with the Bristol ODN on Primary Care and Emergency Department Opt-Out Testing initiatives to reach people who are not in community drug and alcohol treatment services including CBT projects and development work.

The Bath service re-declared hepatitis C micro-elimination after sustaining it for 1 year!

Dorset -

- Hep C U Later handed over the monthly reporting to Waythrough (new lead provider); however, Hep C U Later provide ongoing support with ad-hoc data and their clinical system.
- Hep C U Later created a trend analysis presentation.
- Regular Pan Dorset stakeholder meetings held.
- Supporting with testing in rural areas.
- Identifying people who are on the UKHSA Return to Care database and engaging them in testing.
- Ran the GP records search tool in Weymouth surgery.

Surrey and Borders Partnership NHS Foundation Trust – i Access North West, i Access South West, i Access East (SaBP):

- Monthly meetings held with the Clinical Lead and Data Leads.

- Deep data work carried out with criteria 4 of the hepatitis C micro-elimination criteria and supported changes to business-as-usual processes in the reporting of hepatitis C RNA results.
- Surrey are very close to achieving hepatitis C micro-elimination in one service, however the service want to declare micro-elimination across the whole portfolio.
- Hep C U Later have completed a data dive to explore data anomalies.

Essex Partnership University NHS Trust (EPUT)

- Hep C U Later welcomed Essex Partnership University NHS Trust in July 2025 and commenced working with them to understand the system and key partnership with Open Road Essex
- Worked with the whole system and commissioners to design a bespoke system dashboard on their data.
- Education and testing events have been carried out at the service.
- The Essex team got fully involved with promoting the NHS hepatitis C testing portal for World Hepatitis Day.
- Hep C U Later delivered hepatitis C elimination training to all of Essex STaRS and plan to deliver this to Open Road Essex teams.
- Hep C U Later have suggested changes to business-as-usual processes in relation to the approach to the 'Assessed as not appropriate to test/re-test' NDTMS status.

East London Foundation Trust (ELFT)

East London Foundation Trust joined Hep C U Later part way through 2025.

- Hep C U Later delivered bespoke hepatitis C training to 67 staff across the ELFT services.
- Hep C U Later delivered Cepheid GeneXpert training to the team and the machine has been placed in the service.
- In February 2026 Hep C U Later spent two days with the staff at the Bedford service completing 29 tests and starting two people on treatment.
- Hep C U Later delivered Hep C U Later dashboard and 'magic data' training to staff.
- The teams have met with the ODN and Hepatitis C Trust Peer Support Lead.

Over the last year the Cepheid GeneXpert machine has been placed in the following areas:

- Inclusion Hampshire
- GP Project (return to care)
- Inclusion Stafford
- Milton Keynes CNWL
- East London Trust Bedford

Wales:

Hep C U Later supported Public Health Wales with altering some already existing resources so they could be used on a wider scale. Additionally, Hep C U Later have shared key learning with health board and community drug and alcohol treatment services in Wales on the development of the hepatitis C micro-elimination criteria.

Project Learnings:

1. Data-driven case finding is the primary driver of elimination

- Deep data work consistently unlocked hidden cohorts and supported progression against micro-elimination criteria.
- Standardising data processes and improving data quality (e.g. RNA recording, anomaly resolution) was critical to sustaining elimination.

2. Embedding testing into routine service delivery sustains performance

- Integration of testing into business-as-usual pathways (rather than campaigns alone) enabled sustained high testing levels and micro-elimination maintenance.
- Tools such as GeneXpert placement, portable dashboards, and SOPs improved accessibility and consistency

3. Multi-agency collaboration is essential for scale and reach

- Strong partnerships between NHS Trusts, ODNs, Local Authorities, UKHSA, and peer organisations enabled:
- Better patient tracking (e.g. Return to Care engagement)
- System-wide pathway redesign
- Regular stakeholder forums and MDT structures improved accountability and pace of delivery.

4. Peer-led and outreach models improve engagement with underserved groups

- Use of Hepatitis C Trust peers and outreach (e.g. clinical vans, community NSP distribution) increased testing uptake and re-engagement.

5. Workforce capability and ownership are critical

- Training (clinical + data + micro-elimination criteria) improved staff confidence and consistency.
- Services that achieved sustained elimination typically:
 - Had clearly defined roles/responsibilities

- Embedded hepatitis C into core KPIs and workflows

6. Targeted high-intensity approaches accelerate progress

- High-intensity “test and treat” initiatives and focused data cleanses were effective in closing residual gaps to micro-elimination.

7. Sustainability requires system-level infrastructure, not project dependency

- Development of:
 - Sustainability toolkit
 - Portable dashboards

Enabled transition from programme-led delivery into locally owned, self-sustaining models.

Contributions from Each Party:

Joint Working – March 2022 – September 2024

Gilead Resources

Gilead will directly fund NHS posts to work on this project at a cost of £400,00 per annum, contribute some of its own staff time and expertise, and provide at its discretion further direct financial investment to the project, as follows:

- Hepatitis C Elimination Lead
- Hepatitis C Elimination Project Support (0.6 FTE)
- Hepatitis C Elimination Coordinators (2 FTE)
- Hepatitis C Elimination Data Analysts (2 FTE)
- Hepatitis C Elimination Training Manager (0.7 FTE)

Gilead staff who will contribute time and expertise:

- Regional Market Access – 0.5 FTE
- Gilead Regional Leads – 2.0 FTE

- Therapeutic Specialists – 0.8 FTE

Hep C U Later Resources

In line with previous agreement and additionally:

- 1) NHSAPA will support wider engagement with stakeholders as outlined but not limited to those outlined below:
 - Commissioning Standards for Community Drug Services
 - Workforce Development Standards
 - In Patient Detox Forum
 - Dame Carol Black Ind. Review of Drugs Expert Group
 - Project Adder (Addiction, Diversion, Disruption, Enforcement and Recovery) Expert Group
 - Prison Drug Strategy
 - HMIP/CQC thematic review Drug treatment within Probation
 - Local Integrated Care System (ICS) development in each of trust localities
- 2) Development and Delivery of a Data Road map ensuring all NHSAPA members are reporting the same outcomes in the same methodology correctly

Joint Working – September 2024 - March 2026

Gilead Resources

There will be no direct financial contribution from Gilead Sciences to this project.

2.00 FTE (80 hrs per week) equivalent in Gilead Regional Lead (currently known as Patient Access to Care (PAC) Managers) time dedicated to the joint working project which includes project management support from a Gilead Sciences National Initiatives Lead PAC role (NIL). PAC managers work with Hep C U Later programme coordinators and local stakeholders to provide logistical support and expertise and assist in driving the delivery component of the Hep C U Later programme as outlined in the business case to NHSE in the appendices below. The NIL will support the programme strategically at a national level.

0.5 FTE (20 hours per week) equivalent Regional Market Access Lead (RMax) time to work across whole systems to address barriers identified by Hep C U Later programme coordinators and Gilead Regional Leads that involve commissioners, trust managers or wider policy stakeholders.

Gilead Director level chairmanship of the drug treatment service Hepatitis C Provider Forum which will meet monthly and of which the Hep C U Later will be a member (3 hrs dedicated time

per month).

This equates to an approximate financial value of Gilead time of £375k per annum.

Hep C U Later Resources

Required time for Hep C U Later Programme coordinators / High Intensity Engagement Coordinator to meet, develop and execute local action plans with Gilead Regional Leads and Market Access Leads in support of micro-elimination and sustaining micro-elimination of HCV across all NHSAPA services partnered with the programme (20 hours per week). Based on trust performance and potential for improvement, coordinators will prioritise engagement and support to enable an improved response to Hepatitis C testing and treatment and coordinate and support the activities of the Hep C U Later Data Analysts and Training Manager.

Hep C U Later Programme Lead (20 hours per week) to provide strategic leadership / Direction of the project and management of the team ensuring accountability against tasks and milestones alongside networking and engagement with all system partners.

Project Manager to support the administration and project management of the project monthly and to coordinate Programme Board (Board Meetings) on quarterly basis at which Gilead will have two standing representatives (20 hours per month).

Hep C U Later Programme Lead to meet with Gilead National Initiatives Lead monthly to provide a platform for mutual sharing of learnings, best practice, and project management support and sharing of developed resources (2 hours per month) and to update on regional progress, issues or blocks and barriers to facilitate prioritisation of Gilead resources (2 hours per month).

Hep C U Later Training Manager to be responsible for training and developing packages of care to support best practice interventions (10 hours per week).

Required Data Analysis (Band 6) time (10 hours per week) to collate and support the sharing of non-identifiable patient data in the form of the dashboard on a page (DOAP) and de-identified, aggregate information at service level where NHS Inclusion is the lead provider for HCV testing, referral to HCV treatment service users for upload to a secure client portal in the format agreed by Gilead both on a monthly basis. Working with trust data leads / business teams to improve and report on Hep C outcomes. Data Administration embedded into trust for set periods of time when required.

Hep C U Later to contribute to the development of agendas for and send a representative to attend Gilead HCV Drug Treatment Provider Forum monthly and complete any required follow-up actions arising and agreed at these meetings (5 hours per month).

Hep C U Later to provide at least one representative to engage with and support the delivery of the agreed objectives for Gilead HCV Drug Treatment Provider subgroups (4 hours per month).

For the Hep C U Later programme to provide staff time to provide strategic support Gilead Sciences Hepatitis C patient activation work within Wales, Scotland, and Northern Ireland where it is jointly agreed there is the capacity to do so and where this would not negatively impact on the resource

available to England to include:

- Meetings to provide consultation/advice from experience.
- Attendance and presentations at in-person events such as conferences on work carried out to date.
- Sharing learning from across the programme.
- Sharing resources already developed as part of the prior joint working arrangements.
- Sharing resources already developed as part of the NHSE funded programmes where agreed with NHSE.

In addition, each participating hospital trust will be contributing time and resources to the project to ensure that effective provision is in place to test people at risk, identify and engage people and to ensure specialist treatment is in place at the point of need and that appropriate data is supplied to the Hep C U Later programme team.